Investor Relations

Recent Event

Fiscal Year 2022 Financial Results Conference Call

Latest Financial Results

FY 2022

Fiscal Year Ended Jun 30, 2022

Latest Annual Filing

For Fiscal Year Ending Jun 30, 2021

Email Alerts

Stay informed and receive updates directly to your inbox.

Sign up today

Company Overview

iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of hard-to-target subdominant epitopes along with its sustainable, plant-based protein expression capabilities for cGMP manufacturing. Its FastPharming® Manufacturing System combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic, infectious and autoimmune diseases. The Company’s wholly owned subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with Glycaneering Development Services for advanced recombinant protein engineering.

Investor Contact Information


iBio Inc.
8800 HSC Pkwy
Bryan, TX 77807
T: 979-446-0027

Investor Relations

Stephen Kilmer
T: 646-274-3580

Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.